Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NCGC00378430 is a potent SIX1/EYA2 interaction inhibitor that disrupts the SIX1/EYA2 complex, EMT, and Metastasis.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 22,000 | |||
5 mg | 在庫あり | ¥ 45,500 | |||
10 mg | 在庫あり | ¥ 75,500 | |||
25 mg | 在庫あり | ¥ 128,000 | |||
50 mg | 在庫あり | ¥ 181,000 | |||
100 mg | 在庫あり | ¥ 257,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 52,000 |
説明 | NCGC00378430 is a potent SIX1/EYA2 interaction inhibitor that disrupts the SIX1/EYA2 complex, EMT, and Metastasis. |
In vitro | NCGC00378430 reduces the SIX1/EYA2 interaction.?8430 partially reversed transcriptional and metabolic profiles mediated by SIX1 overexpression and reversed SIX1-induced TGFβ signaling and EMT. |
In vivo | NCGC00378430?was well tolerated when delivered to mice and significantly suppressed breast cancer associated metastasis in vivo without significantly altering primary tumor growth. |
分子量 | 441.5 |
分子式 | C22H23N3O5S |
CAS No. | 920650-00-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90 mg/mL (203.85 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
NCGC00378430 920650-00-6 Metabolism Others Phosphatase Inhibitor T47D E-CAD MCF7 TGF-β inhibit SIX1 p-Smad3 breast EMT cancer FN1 transcriptional NCGC 00378430 NCGC-00378430 EYA2 inhibitor